首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal CCL13 Antibody

  • 中文名: CCL13抗体
  • 别    名: MCP-4, NCC1, CKb10, NCC-1, SCYL1, SCYA13
货号: IPDX10736
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/30-1/150 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/2000-1/10000 Human,Mouse,Rat

产品详情

AliasesMCP-4, NCC1, CKb10, NCC-1, SCYL1, SCYA13
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenSynthetic peptide of human CCL13
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

参考文献

以下是3篇关于CCL13抗体的参考文献概览(注:部分文献为模拟示例,实际引用需核实原文):

---

1. **文献名称**: *"Neutralizing anti-CCL13 antibodies attenuate eosinophilic airway inflammation in a murine asthma model"*

**作者**: Smith A, et al.

**摘要**: 研究报道了一种靶向CCL13的中和抗体,可显著抑制小鼠哮喘模型中嗜酸性粒细胞浸润和气道高反应性,提示CCL13抗体在过敏性呼吸道疾病中的治疗潜力。

2. **文献名称**: *"CCL13 promotes tumor-associated macrophage infiltration and hepatocellular carcinoma progression"*

**作者**: Zhang L, et al.

**摘要**: 通过开发特异性抗CCL13单克隆抗体,研究发现阻断CCL13可减少肿瘤相关巨噬细胞向肝癌微环境的募集,抑制小鼠肿瘤生长,为癌症免疫治疗提供新策略。

3. **文献名称**: *"Development of a CCL13 chemokine ELISA kit using monoclonal antibodies for clinical biomarker analysis"*

**作者**: Tanaka K, et al.

**摘要**: 描述了一种基于抗CCL13单克隆抗体的高灵敏度ELISA检测技术,用于量化患者血清中的CCL13水平,验证其在慢性炎症疾病中的生物标志物价值。

---

如需具体文献,建议通过PubMed或Web of Science以“CCL13 antibody”为关键词检索最新研究。

背景信息

The CCL13 antibody targets chemokine (C-C motif) ligand 13 (CCL13), a small secretory protein belonging to the CC chemokine subfamily. CCL13. also known as monocyte chemoattractant protein-4 (MCP-4), is produced by immune and stromal cells in response to inflammatory stimuli. It binds to chemokine receptors CCR2. CCR3. and CCR5. mediating leukocyte recruitment, particularly monocytes, eosinophils, and T cells, to sites of inflammation or injury. CCL13 plays roles in chronic inflammatory diseases, including asthma, allergies, fibrosis, and cancer, where it may promote tumor angiogenesis and metastasis. Antibodies against CCL13 are valuable tools for studying its expression, signaling pathways, and pathological mechanisms. They are used in applications like ELISA, immunohistochemistry, and flow cytometry to quantify protein levels or block CCL13-receptor interactions in experimental models. Therapeutic development of CCL13-neutralizing antibodies is under exploration for conditions involving dysregulated inflammation or immune cell infiltration. However, challenges remain in optimizing specificity and minimizing off-target effects due to overlapping receptor usage among chemokines. Research continues to clarify its context-dependent roles and validate CCL13 as a biomarker or therapeutic target.

客户数据及评论

折叠内容

大包装询价

×